Evidence map›Paper›PMID 11752153›Full record

ArticleJournal of virology2002

Human papillomavirus type 16 E7 maintains elevated levels of the cdc25A tyrosine phosphatase during deregulation of cell cycle arrest.

Don X Nguyen, Thomas F Westbrook, Dennis J McCance

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 83 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. The role of Cdc25A in the regulation of cell proliferation and apoptosis.Anti-cancer agents in medicinal chemistry · 2012
    Review
  18. Review
  19. Histone deacetylases in viral infections.Clinical epigenetics · 2010
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Don X NguyenDepartment of Microbiology and Immunology, The Cancer Center, University of Rochester, Rochester, New York 14642, USA.
Thomas F Westbrook
Dennis J McCance
University of Rochester · US

Funding

HPV6 AND 16 EFFECTS ON EPITHELIAL CELL DIFFERENTIATIONR01AI030798 · NIAID · UNIVERSITY OF ROCHESTER · PI MCCANCE, DENNIS J. · 1990 to 2005
$1.6M
NIAID NIH HHS AI 30798NIAID NIH HHS R01 AI030798
6 · The paper itself

Abstract

Essential to the oncogenic properties of human papillomavirus type 16 (HPV-16) are the activities encoded by the early gene product E7. HPV-16 E7 (E7.16) binds to cellular factors involved in cell cycle regulation and differentiation. These include the retinoblastoma tumor suppressor protein (Rb) and histone deacetylase (HDAC) complexes. While the biological significance of these interactions remains unclear, E7 is believed to help maintain cells in a proliferative state, thus establishing an environment that is conducive to viral replication. Most pathways that govern cell growth converge on downstream effectors. Among these is the cdc25A tyrosine phosphatase. cdc25A is required for G(1)/S transition, and its deregulation is associated with carcinogenesis. Considering the importance of cdc25A in cell cycle progression, it represents a relevant target for viral oncoproteins. Accordingly, the present study focuses on the putative deregulation of cdc25A by E7.16. Our results indicate that E7.16 can impede growth arrest induced during serum starvation and keratinocyte differentiation. Importantly, these E7-specific phenotypes correlate with elevated cdc25A steady-state levels. Reporter assays performed with NIH 3T3 cell lines and human keratinocytes indicate that E7 can transactivate the cdc25A promoter. In addition, transcriptional activation by E7.16 requires the distal E2F site within the cdc25A promoter. We further demonstrate that the ability of E7 to abrogate cell cycle arrest, activate cdc25A transcription, and increase cdc25A protein levels requires intact Rb and HDAC-1 binding domains. Finally, by using the cdk inhibitor roscovitine, we reveal that E7 activates the cdc25A promoter independently of cell cycle progression and cdk activity. Consequently, we propose that E7.16 can directly target cdc25A transcription and maintains cdc25A gene expression by disrupting Rb/E2F/HDAC-1 repressor complexes.

Indexed as

CDC2-CDC28 KinasesCell CycleCell Cycle ProteinsDNA-Binding Proteins3T3 CellsAnimalsBinding Sitescdc25 PhosphatasesCell DifferentiationCell DivisionCells, CulturedCyclin-Dependent Kinase 2Cyclin-Dependent KinasesE2F Transcription FactorsEnzyme InductionHistone Deacetylase 1CDC25A protein, humanCdc25a protein, mousecdc25 PhosphatasesCDC2-CDC28 KinasesCDK2 protein, humanCdk2 protein, mouseCell Cycle ProteinsCyclin-Dependent Kinase 2Cyclin-Dependent KinasesDNA-Binding ProteinsE2F Transcription FactorsHDAC1 protein, humanHistone Deacetylase 1Histone Deacetylasesoncogene protein E7, Human papillomavirus type 16Oncogene Proteins, ViralPapillomavirus E7 ProteinsProtein Serine-Threonine KinasesRetinoblastoma ProteinRNA, MessengerTranscription Factors

Identifiers

PMID11752153
PMCPMC136809
OpenAlexW2003393099

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.